24 completed, 11 recruiting, 9 unknown, 5 terminated. 62 Phase 2, 14 Phase 3, 13 Phase 1.
Follow Orbital Diseases: new trials by email Literature Review of Orbital Diseases trials Research Report on Orbital Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease BHV-1300 - Graves' Disease | Phase 2 / Phase 3 | Not yet recruiting | Biohaven Therapeutics Ltd. | 356 | 2026-10-01 | 2026-10-28 |
| Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy Teprotumumab N01, Intravenous Methylprednisolone (IVMP) - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Not yet recruiting | Sun Yat-sen University | 60 | 2026-08-01 | 2026-05-19 |
| A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old Felzartamab, Placebo - Graves' Disease | Phase 2 | Recruiting | Biogen | 60 | 2026-07-30 | 2026-11-12 |
| Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease Experimental: YB-101, Placebo YB-101 - Graves' Disease | Phase 2 | Recruiting | Yarrow Bioscience, Inc. | 232 | 2026-06-10 | 2026-10-30 |
| An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease AMG 732 - Thyroid Eye Disease | Phase 2 | Recruiting | Amgen | 30 | 2026-05-07 | 2026-07-23 |
| A Study of VV-14305 for the Treatment of Thyroid Eye Disease VV-14305, Sham (No Treatment) - Thyroid Eye Disease (TED) | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 135 | 2026-05-01 | 2026-08-27 |
| Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease Tofacitinib - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 8 | 2026-04-24 | 2026-04-29 |
| Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz WP1302, WP1302 placebo, methimazole - Graves Disease | Phase 2 | Suspended | Worg Biotherapeutics Inc. | 176 | 2026-03-31 | 2025-05-08 |
| An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) NTB003, NTB003 and Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Not yet recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 74 | 2026-03-01 | 2026-03-10 |
| A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) IMVT-1402 - Graves' Disease | Phase 2 | Enrolling by invitation | Immunovant Sciences GmbH | 372 | 2026-01-26 | 2026-09-29 |
| A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease Rilzabrutinib dose 1, Rilzabrutinib dose 2 - Graves' Disease | Phase 2 | Recruiting | Sanofi | 30 | 2025-09-02 | 2026-10-28 |
| Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease Ergocalciferol 50,000 IU, Methimazole - Graves Disease, Graves' Disease | Phase 2 | Active not recruiting | Northwell Health | 30 | 2025-08-25 | 2026-10-23 |
| A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease IMVT-1402, Placebo - Graves' Disease | Phase 2 | Recruiting | Immunovant Sciences GmbH | 210 | 2025-06-19 | 2026-10-30 |
| A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease IMVT-1402, Placebo - Graves' Disease | Phase 2 | Recruiting | Immunovant Sciences GmbH | 240 | 2024-12-17 | 2026-08-25 |
| A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease IBI311 (20 mg), IBI311 (3-20 mg), IBI311 (10 mg) - Thyroid Eye Disease | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 38 | 2024-09-04 | 2025-10-03 |
| A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease AMG 732, Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Active not recruiting | Amgen | 94 | 2024-05-30 | 2026-08-10 |
| A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease LASN01, Placebo - Thyroid Eye Disease, Graves Ophthalmopathy | Phase 2 | Completed | Lassen Therapeutics Inc. | 41 | 2024-03-05 | 2026-03-09 |
| A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease TOUR006 - 20 MG, Placebo, TOUR006 - 50 MG - Thyroid Eye Disease | Phase 2 | Active not recruiting | Tourmaline Bio, Inc., a Novartis Company | 79 | 2024-02-19 | 2026-04-23 |
| Graves' Disease Remission Study: MycoMeth Combo Mycophenolate Mofetil, Oral, 250 Mg, methimazole, oral, 10mg - Graves' Disease | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Xiamen University | 205 | 2023-10-16 | 2024-02-28 |
Showing 20 of 62. Sign in to see all of them.
Graves Ophthalmopathy (39) · Graves Disease (26) · Hyperthyroidism (12) · Eye Diseases (8) · Exophthalmos (6) · Thyroid Diseases (6) · Endocrine System Diseases (5) · Autoimmune Diseases (3) · Diplopia (2) · Eye Diseases, Hereditary (2) · Hashimoto Disease (2) · Immune System Diseases (2) · Neoplasms (2) · Abdominal Pain (1)
Goiter (58) · Immune System Diseases (57) · Autoimmune Diseases (56) · Eye Diseases (54) · Endocrine System Diseases (53) · Exophthalmos (52) · Thyroid Diseases (52) · Hyperthyroidism (46) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (40) · Genetic Diseases, Inborn (39) · Eye Diseases, Hereditary (37) · Graves Disease (32) · Pathological Conditions, Signs and Symptoms (6) · Nervous System Diseases (4)
Methylprednisolone (6) · Rituximab (5) · Methimazole (4) · Methylprednisolone Hemisuccinate (4) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (2) · Atorvastatin (2) · Chlortetracycline (2) · Doxycycline (2) · Sirolimus (2) · sulfadiazine, tetroxoprim drug combination (2) · teprotumumab (2) · tocilizumab (2) · Azithromycin (1) · Botulinum Toxins, Type A (1) · Bupivacaine (1)
Immunovant Sciences GmbH (6) · Sun Yat-sen University (5) · Amgen (3) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (2) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Iran University of Medical Sciences (2) · Novartis Pharmaceuticals (2) · Odense University Hospital (2) · Sling Therapeutics, Inc. (2) · The First Affiliated Hospital of Xiamen University (2) · University of Pisa (2) · ACELYRIN Inc. (1) · Assiut University (1) · Biogen (1) · Biohaven Therapeutics Ltd. (1)
United States (26) · Italy (13) · China (11) · Spain (10) · United Kingdom (9) · Germany (7) · Australia (6) · Canada (5) · Poland (5) · Georgia (3) · Greece (3) · Hungary (3) · Iran (3) · Latvia (3) · New Zealand (3)
Dan Liang, MD (3) · Fangsen Xiao, MD (2) · Mohsen B Kashkouli, MD (2) · Ahmed Abdelal, MD (1) · Alan B Scott, MD (1) · Arezou Khosroshahi, MD (1) · Babak Babsharif, MD (1) · Dan Liang (1) · Daniel El-Fassi, MD (1) · Dyah Purnamasari, M.D., Ph.D (1) · Dylan Lee, MD (1) · Eric B Suhler, MD (1)
PMID 27797318, PMID 10427152, PMID 12050214, PMID 16864757, PMID 18299459, PMID 20126486, PMID 20739336, PMID 22983830, PMID 23204220, PMID 24374976, PMID 24651704, PMID 24652467, PMID 25343233, PMID 25667206, PMID 26221138, PMID 26670972, PMID 27269295, PMID 27272078, PMID 27474763, PMID 27521067, PMID 28467880, PMID 29396246, PMID 30912336, PMID 31512728, PMID 32055040, PMID 32616746, PMID 32929476, PMID 33768488, PMID 34149627, PMID 34592164, PMID 34598995, PMID 35223896, PMID 35959915, PMID 36173609, PMID 36346684, PMID 41066129, PMID 42660999, PMID 9322804
2025 (2), 2004 (1), 2009 (1), 2014 (1), 2015 (1), 2023 (1), R01DK077814 (1), UL1RR024150 (1)